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Abstract 25 
The major histocompatibility complex (MHC) class I region in mammals contains both classical 26 
and non-classical MHC class I genes. Classical MHC class I molecules present antigenic peptides to 27 
cytotoxic T lymphocytes, whereas non-classical MHC class I molecules have a variety of functions. 28 
Both classical and non-classical MHC molecules interact with natural killer cell receptors, and may 29 
under some circumstances prevent cell death by natural killer cytotoxicity. The E5 oncoprotein of 30 
BPV-4 down-regulates the expression of classical MHC class I on the cell surface and retains the 31 
complex in the Golgi apparatus. The inhibition of classical MHC class I to the cell surface results 32 
from both the impaired acidification of the Golgi, due to the interaction of E5 with subunit c of the 33 
H+ V-ATPase, and to the physical binding of E5 to the heavy chain of MHC class I. Despite the 34 
profound effect of E5 on classical MHC class I, E5 does not retain a non-classical MHC class I in 35 
the Golgi, does not inhibit its transport to the cell surface and does not bind its heavy chain. We 36 
conclude that, as is the case for HPV-16 E5, BPV-4 E5 does not down-regulate certain non-classical 37 
MHC class I, potentially providing a mechanism for the escape of the infected cell from attack by 38 
both cytotoxic T lymphocytes and NK cells.  39 
 40 
Introduction 41 
Viruses have to evade the innate and adaptive host immune response to establish infection and 42 
persist at least until new progeny virus is released. Many viruses have developed the ability of 43 
down-regulating the major histocompatibility complex (MHC) class I (Piguet, 2005), thus avoiding 44 
lysis by cytotoxic T lymphocytes (CTL;  effector cells capable of recognising and destroying 45 
transformed or infected cells), while not interfering with expression of some non-classical MHC 46 
class I genes. Some non-classical MHC class I molecules, in common with classical class I 47 
molecules, engage both inhibitory and activating receptors of natural killer (NK) cells, components 48 
of the innate immune response, which may recognise and destroy cells with low levels of MHC 49 
class I. The absence of down-regulation of some non-classical MHC class I genes, or their up-50 
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regulation, by virus may result in the failure of NK cells to kill virus-infected cells and allows virus 51 
to escape both CTL and NK killing (Cohen et al., 1999; Tomasec et al., 2000; Wang et al., 2002).  52 
Papillomaviruses (PV) are small oncogenic viruses that infect mucosal and cutaneous epithelia 53 
causing benign hyperproliferative lesions (papillomas, warts, condylomas). 54 
Infection by PV is under immunological control; this is demonstrated by epidemiological studies 55 
showing that in both human and animal hosts with genetic, iatrogenic or acquired cell-mediated 56 
immune deficiencies, PV lesions show increased persistence and enhanced neoplastic progression 57 
(see O'Brien and Campo, 2002, for review). However, even in immunocompetent individuals, 58 
despite expressing abundant viral protein, PV persist for a significant period of time, usually 59 
spanning several months, and even years, before activation of the host immune system. This lack of 60 
recognition suggests the host immune system is unaware of, and/or disabled by, PV infection. 61 
Indeed, the ability of PV to persist has been attributed to several causes: the nature of the virus life 62 
cycle, which takes place wholly in the epithelium and therefore prevents high levels of the viral 63 
proteins having access to the immune cells; the entry of PV to a latent state with very low levels of 64 
expression of viral antigens; and, as demonstrated recently, the ability of the virus to directly 65 
subvert and evade the host immune response (Frazer et al., 1999; O'Brien and Campo, 2002; Tindle, 66 
2002). It is likely that the contribution of each of these factors results in a delay or prevention of 67 
resolution of infection. 68 
It is becoming clear that the oncoproteins of PV can interfere with the host immunosurveillance and 69 
response (O'Brien and Campo, 2002). We have shown that the E5 oncoprotein of both BPV and 70 
HPV inhibits the transport of MHC class I to the cell surface and retains it in the Golgi apparatus 71 
(Araibi et al., 2004; Ashrafi et al., 2002, 2005; Marchetti et al., 2002). Additionally we have shown 72 
that BPV-4 E5 interacts physically with bovine MHC class I heavy chain (HC) and that both this 73 
interaction and the down-regulation of the complex require the C-terminus domain of E5 (Marchetti 74 
et al., 2005).  75 
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Although effectively down-regulating surface classical MHC class I, HPV-16 E5 does not interfere 76 
with the transport of non-classical MHC class I to the cell surface (Ashrafi et al., 2005). It is not 77 
known if this is the case also for BPV E5.  78 
Recently, nine putative non-classical class I sequences (N*50001-N*50501, see 79 
http://www.ebi.ac.uk/ipd/mhc/bola/) have been identified in cattle cDNAs, most of which have not 80 
yet been functionally characterized. N*50001 (GenBank accession: AY188807) was first identified 81 
in 1995 when it was termed HD59 (Ellis et al., 1996) and subsequently was mapped to a region of 82 
the cattle MHC containing several classical class I genes (Di Palma et al. , 2002). N*50001 encodes 83 
a HC with a truncated cytoplasmic domain (8 rather than 28 amino acids), and in this sense 84 
resembles human HLA-G (Geraghty et al.,  1987).  85 
Here we show that BPV-4 E5 cannot down-regulate expression of N*50001 MHC class I complex 86 
or interact with N*50001 HC, suggesting that, like other viruses, BPV is potentially capable of 87 
evading CTL and NK killing of infected cells. 88 
 89 
 90 
Results 91 
We have shown that BPV-4 E5 binds to bovine class I HC and have mapped the HC-interacting 92 
domain of E5 to its C-terminus end (Marchetti et al., 2005). We have also shown that HPV-16 E5 93 
down-regulates classical HLA I (MHC class I) but not non-classical HLA-E (Ashrafi et al., 2005). 94 
To determine whether BPV-4 E5, like HPV-16 E5, is incapable of down-regulating certain non-95 
classical MHC genes, we took advantage of a recently described gene in the bovine MHC class I 96 
cluster, N*50001 (Di Palma et al., 2002).  97 
N*50001 has an early stop codon in the sequence encoding the intra-cytoplasmic domain 98 
(producing a C-terminal truncated HC), has a number of base pairs substitutions leading to unusual 99 
amino acids (see Figure 1), has a large deletion in the 3’UTR, and significant differences in the 100 
promoter region compared to classical class I genes (data not shown). It is prone to alternative 101 
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splicing, in common with some other non-classical class I genes, and the isoform most often found 102 
was used in this study (Figure 1). This isoform contains a small section of intron 4 resulting in 4 103 
additional amino acids at the end of the alpha 3 domain. N*50001 is recognised by mAb IL-A88, a 104 
mAb that recognises a monomorphic determinant on all bovine classical MHC class I molecules 105 
(Toye et al., 1990) (Figure 4). mAb IL-A88 was used throughout the present work.  106 
 107 
Generation of mouse P815 cells expressing bovine MHC class I. It is not possible to analyse the 108 
expression or the function of N*50001 in bovine cells (in vivo) because there is no specific antibody 109 
for its protein. To investigate the properties of this gene, its cDNA was introduced into the mouse 110 
cell line P815, giving rise to P815-N*50001 cells. P815-N*01301 cells were generated in a similar 111 
way. There was no need to co-transfect the bovine β2 microglobulin (β2m) gene with the bovine 112 
MHC HC genes into P815 cells because the bovine class I HC associates with mouse β2m, and 113 
when the complex reaches the cell surface it rapidly exchanges mouse β2m with bovine β2m 114 
provided by the foetal calf serum in the culture medium (Ellis et al., 2005). Both N*01301 and 115 
N*50001 are expressed in P815 cells and transported to the cell surface (see below and Figure 3).  116 
 117 
Stable introduction and expression of BPV-4 E5 into P815-N*01301 and P815-N*50001 cells. 118 
Any interaction between E5 and N*50001 cannot be studied in bovine cells, such as our well 119 
characterised PalF cell lines, as there are no specific antibodies for this HC and the mAb IL-A88, 120 
which recognises N*50001, recognises all other MHC class I HC. The P815-N*01301 and P815-121 
N*50001 cells gave us an opportunity to analyse the functional relationship between E5 and 122 
N*50001 independently from the interaction between E5 and N*01301. We introduced E5 into 123 
these cells, either expressed from the murine MuLV transcriptional promoter in pZipneo (pz4E5), 124 
or expressed from the IE promoter of HCMV in pcDNA3 (pc4E5). The corresponding empty 125 
vectors were also introduced into the P815-N*01301 and P815-N*50001 cells as controls. We 126 
generated the following cell lines: P815-N*01301-pz4E5, P815-N*01301-pc4E5, P815-N*01301-127 
 6
pZip, P815-N*01301-pcDNA, P815-N*50001-pz4E5, P815-N*50001-pc4E5, P815-N*50001-pZip 128 
and P815-N*50001-pcDNA.  129 
We determined the expression of E5 by quantitative RT-PCR. There was little or no difference in 130 
E5 expression whether expressed from the MLV LTR or the CMV IE promoter, either in P815-131 
N*01301 or in P815-N*50001 cells (Figure 2).  132 
 133 
Expression of bovine MHC class I in P815 cells expressing BPV-4 E5.  134 
The expression of N*01301 or N*50001 was analysed by flow cytometry. As expected, E5 induced 135 
a remarkable down-regulation of N*01301-containing MHC class I (Figure 3). There was very little 136 
surface MHC class I, with a reduction of more than five fold compared to control cells carrying 137 
empty vector, and also the amount of total (surface plus intra-cytoplasmic) MHC class I was less 138 
than half of that in control cells. The results shown in Figure 3A were obtained with P815-139 
N*01301-pc4E5 cells, but the results obtained with P815-N*01301-pz4E5 cells were essentially 140 
identical (data not shown). These results confirm that 4E5 has a drastic effect on the expression and 141 
transport of MHC class I (Ashrafi et al., 2002; Marchetti et al., 2005). The results also show 142 
conclusively that 4E5 is capable of down-regulating MHC class I in the absence of any other viral 143 
oncogene.   144 
In contrast to what was observed with N*01301, N*50001 was not at all affected by E5 and the 145 
levels of surface or total MHC were indistinguishable from those in control cells (Figure 3). 146 
Identical results were obtained with P815- N*50001-pz4E5 cells (data not shown).  147 
The decrease in N*01301 expression but not in N*50001 expression was confirmed by western 148 
blotting. There was less N*01301 expressed in P815-N*01301-pc4E5 or P815-N*01301-pzE5 cells 149 
than in the control cells (Figure 4A); on the contrary, the expression of N*50001 was unchanged in 150 
P815-N*50001-pc4E5 or P815-N*50001-pz4E5 cells, although in control cells it was lower than 151 
that of N*01301 (Figure 4A). It has to be noted that mAb IL-A88 did not react with mouse MHC 152 
class I in the parental P815 cells (Figure 4A, middle lane), and therefore a possible cross-reaction 153 
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with bovine and mouse MHC class I can be discounted.  Additionally mAb IL-A88 did not react 154 
with mouse MHC class I in flow cytometry experiments with parental P815 cells (data not shown) 155 
confirming lack of cross-reaction.  156 
 157 
Turnover of N*01301 and N*50001 in P815-4E5 cells.  158 
To investigate the reasons for the decreased expression of N*01301 in the cells expressing 4E5, the 159 
half life of the HC was measured by inhibiting the translation of new proteins with cyclohexamide 160 
and by following the turnover of HC by western blotting. In control cells, N*01301 was stable and 161 
could still be detected after 24 hours of treatment; in remarkable contrast, in the 4E5-expressing 162 
cells N*01301 was unstable and was practically undetectable after 10 hours (Figure 4B). There was 163 
no difference between the stability of N*50001 in control or 4E5-expressing cells; in both cases 164 
N*50001 HC was still detectable after 24 hours of treatment, comparable to that of N*01301 in 165 
control cells (Figure 4B). These results confirm the general inhibition of classical MHC class I 166 
expression by E5, from stability of the HC protein to the transport of the class I complex to the cell 167 
surface (Araibi et al., 2004; Ashrafi et al., 2002, 2005; Marchetti et al., 2002, 2005). The results also 168 
show that E5 has no effect on the expression, half-life and transport of non-classical N*50001-169 
MHC class I. 170 
 171 
Localisation of classical and non-classical MHC class I in P815-4E5 cells.  172 
In PalF-4E5 cells, E5 retains the MHC class I in the Golgi apparatus (Marchetti et al., 2002). We 173 
wondered whether the reduction in surface N*01301-MHC class I was also due to the retention of 174 
residual complex in the Golgi. We performed two-colour confocal immunofluorescence in the 175 
various P815 cell lines where MHC class I was detected with mAb IL-A88 and a FITC-conjugated 176 
secondary antibody, and the Golgi apparatus was detected with Bodipy Ceramide-Texas Red. In all 177 
control cells, whether expressing N*01301 or N*50001, MHC was both associated with the Golgi 178 
membranes and clearly on the cell surface (Figure 5). In contrast the cellular localisation of 179 
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N*01301- and N*50001-MHC class I was markedly different in P815 cells expressing c4E5 or 180 
z4E5. Classical N*01301-MHC class I was totally associated with Golgi membranes and no 181 
complex was detectable on the cell surface with this technique (Figure 5), whereas, in sharp 182 
contrast, N*50001-MHC was clearly on the cell surface, in addition to the Golgi membranes 183 
(Figure 5), and its localisation pattern was no different from the one in control cells. Again, no 184 
reaction was observed in parental P815 cells (data not shown). 185 
The localisation of N*50001 was analysed also in bovine PalF control cells (transformed but 186 
without E5) and in PalF-4E5 cells (transformed and expressing E5) (Ashrafi et al., 2000; Pennie et 187 
al., 1993). FLAG-tagged N*50001 was detected both in the Golgi apparatus and on the cell surface 188 
in both control and PalF-4E5 cells, while a GFP fusion form of classical HC B2705 was wholly 189 
confined to the misshapen Golgi apparatus in the PalF-4E5 cells, but not in the control cells (data 190 
not shown), as previously reported (Marchetti et al., 2002). The results obtained in both P815 and 191 
PalF cells show beyond doubt that E5 is incapable of inhibiting the transport of N*50001-MHC 192 
complex from the Golgi compartment to the surface of the cell. 193 
 194 
Physical interaction between E5 and HC. E5 and N*01301 HC interact physically and we have 195 
proposed that this interaction contributes to the down-regulation of the HC and the retention of the 196 
complex in the Golgi (Marchetti et al., 2005). Therefore we asked whether E5 would complex with 197 
N*50001 HC and used in vitro co-precipitation assays as in vitro interaction between E5 and HC is 198 
a faithful read-out for in vivo interaction (Marchetti et al., 2005; Ashrafi et al., submitted). As 199 
before, we in vitro transcribed/translated E5, N*01301 and N*50001 HC, and precipitated the HC 200 
with mAb IL-A88. Whereas E5 co-precipitated with N*01301 HC, it did not do so with N*50001 201 
HC (Figure 6A). The lack of interaction between E5 and N*50001 was confirmed by a competition 202 
experiment in which unlabelled N*50001 was added to labelled E5 and labelled N*01301. 203 
Unlabelled N*50001 failed to prevent the interaction between E5 and N*01301 (Figure 6A), 204 
confirming that it cannot bind to E5.  205 
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As described above, N*50001 lacks the C-terminus intra-cytoplasmic tail of classical MHC class I 206 
HC and is 19 amino acids shorter than N*01301 (Figure 1). Given the absence of interaction 207 
between E5 and N*50001 we wondered whether the intra-cytoplasmic domain of class I HC was 208 
responsible for binding to E5. We made a C-terminus truncation mutant of N*01301 HC lacking the 209 
final 19 amino acid residues and performed in vitro co-IP experiments with 4E5. This mutant co-210 
precipitated with 4E5 (data not shown) showing that the interaction between HC and 4E5 does not 211 
involve the C-terminus intracytoplasmic domain of HC. Furthermore, N*01301 HC bound E5 212 
whether tagged with V5-His at its C-terminus, like N*50001, or not (data not shown), 213 
demonstrating that the C-terminus epitope has no effect on the interaction. 214 
We corroborated the in vitro interaction between E5 and HC in a “pull-down co-215 
immunoprecipitation” experiment. Protein lysates for P815 parental cells, P815-N*01301 and 216 
P815-N*50001 cells were incubated with labelled E5 and immunoprecipitated with mAb IL-A88.  217 
As expected, no E5 could be precipitated from P815 control cells or P815-N*50001 cells, while E5 218 
co-precipitated with N*01301 HC in P815-N*01301 cells (Figure 6B). 219 
Taken together, the results presented above lead to the firm conclusion that E5 does not interfere 220 
with the biosynthetic pathway of non-classical N*50001 MHC class I.  221 
 222 
Discussion 223 
Viruses and classical and non-classical MHC class I. It is well-documented that many viruses 224 
evade the host immune system by interfering with the antigen processing and presentation pathways 225 
(Piguet, 2005). These viral mechanisms often target MHC class I, and there are several examples of 226 
discrimination between classical and non-classical class I. While classical class I expression is most 227 
often down-regulated by viral interference at one or more points in the pathway between 228 
transcription and cell-surface expression, expression of non-classical class I genes usually remains 229 
normal (Cohen et al., 1999; Tomasec et al., 2000; Wang et al., 2002). It has been proposed that this 230 
enables the virus-infected cell to evade cytotoxic T cell responses while at the same time sending 231 
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inhibitory signals to NK cells via expression of one or more non-classical class I genes. This relates 232 
to engagement of inhibitory NK receptors by non-classical class I molecules (Borrego et al., 2005; 233 
Hofmeister and Weiss, 2003).  234 
 235 
Non-classical MHC class I in cattle. There is considerable evidence that N*50001 and related 236 
alleles in cattle are encoded by a non-classical MHC class I gene. The classification of N*50001 237 
(and related alleles) as non-classical is based on several criteria, namely association with a number 238 
of unrelated MHC haplotypes (at least one of this set of alleles is present on all MHC haplotypes 239 
examined; Ellis, unpublished data), lack of significant polymorphism, a truncated cytoplasmic 240 
domain (8 rather than 28 amino acids), unusual amino acid substitutions throughout, a characteristic 241 
motif within the transmembrane domain, a large deletion in the 3’ UTR and significant differences 242 
in the 5’ upstream region in comparison to classical class I genes. These alleles may be widely 243 
transcribed, and there is currently no evidence to suggest tissue-specific expression (Davies et al., 244 
2004); Ellis, unpublished data). In addition, a number of alternatively spliced transcripts of 245 
N*50001 can be found (Ellis, unpublished data), a characteristic seen in non-classical class I genes 246 
in other species, most notably HLA-G (Riteau et al., 2001). N*50001 and related alleles are 247 
transcribed at relatively low levels in peripheral blood lymphocytes, and at slightly higher levels in 248 
trophoblast tissue during pregnancy (Davies et al., 2004), in common with some other putative non-249 
classical cattle MHC class I alleles.  250 
 251 
BPV-4 E5 and MHC class I. Because there is no monoclonal antibody available which exclusively 252 
recognizes non-classical class I molecules, to study the relationship of BPV-4 E5 with classical and 253 
non-classical MHC I, we separately expressed a classical, N*01301, and a non-classical, N*50001, 254 
allele in mouse P815 cells and subsequently introduced E5 in these cells. This proved to be a 255 
powerful system which has confirmed that E5 down-regulates classical MHC class I, while it does 256 
not interfere with the biosynthetic pathway of this non-classical MHC class I.  257 
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 258 
BPV-4 E5 and classical MHC class I. As in bovine PalF cells (Marchetti et al., 2005), E5 down-259 
regulates classical MHC class I at more than one level. However, in PalF cells, E5 was co-260 
expressed with E6, E7 and activated ras (Ashrafi et al., 2000), leaving open the possibility, albeit 261 
remote, that down-regulation of MHC class I was due to a functional interaction between the viral 262 
and cellular oncoproteins. In P815 cells, E5 profoundly inhibits classical MHC class I in the 263 
absence of other viral or cellular oncoproteins. E5 impacts on classical MHC class I at several 264 
levels: transcription of the HC gene, expression of protein and transport of the complex to the cell 265 
surface (Marchetti et al., 2005). Transcription of the bovine N*01301 HC cannot be analysed in 266 
P815 cells: E5 inhibits transcription from the homologous promoter of the HC gene (Marchetti et 267 
al., 2005), while in P815 cells the N*01301 HC gene is under the control of the CMV IE promoter, 268 
which is not affected by E5 (data not shown). In P815 cells, in addition to blocking MHC class I in 269 
the Golgi apparatus, E5 induces the degradation of N*01301 HC. In control cells, the half-life of the 270 
HC is approximately 20 hours, whereas in the presence of E5 its half-life is dramatically reduced to 271 
less than 5 hours.  We do not yet know how E5 induces degradation of HC. However, we have 272 
commented before (Marchetti et al., 2005) on the similarities between E5 and HIV 1 Nef, and it is 273 
interesting to note that Nef re-directs HC to the lysosomes for degradation through the simultaneous 274 
interaction with HC and with the adaptor protein 1 (AP-1) complex (Roeth et al., 2004), and that 275 
inhibitors of lysosomes (in conjunction with interferon treatment) restores the expression of HC in 276 
PalF-4E5 cells (Marchetti et al., 2005). It is thus possible that E5 too interacts with both HC and 277 
AP-1 inducing lysosomal degradation of HC, but this remains to be elucidated. 278 
 279 
BPV-4 E5 and non-classical MHC class I. In marked contrast to its inhibitory effect on classical 280 
MHC class I, E5 does not affect the non-classical MHC class I N*50001. This conclusion is based 281 
on numerous pieces of evidence. N*50001 reaches the cell surface, N*50001 HC is expressed to the 282 
same levels as in control cells and its half-life is not affected, and crucially E5 does not interact with 283 
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N*50001 HC. This last point is further corroborated by the inability of N*50001 HC to inhibit the 284 
formation of the complex between E5 and N*01301 HC in vitro. Moreover, the finding that the 285 
half-life of N*50001 HC is not affected by E5 supports our hypothesis that binding to HC is needed 286 
for HC degradation. 287 
A major difference between classical N*01301 and non-classical N*50001 HC is the truncation of 288 
the intracytoplasmic domain in the latter, but the interaction with 4E5 does not take place via this 289 
domain. This finding contrasts with the binding of Nef to the intracytoplasmic domain of HLA-A 290 
and with the observation that the inability of Nef to bind some non-classical HLA resides in amino 291 
acid differences in the intracytoplasmic domain of HLA-E and the absence of the domain in HLA-G 292 
(Pizzato et al., 2004; Williams et al., 2002). There are several amino acid differences throughout the 293 
extracellular domains between classical N*01301 and non-classical N*50001 HC (Figure 1), but 294 
which one of these differences is responsible for the differential interaction with E5 remains to be 295 
established. 296 
 297 
Biological significance of the lack of down-regulation of non-classical MHC class I by E5. The lack 298 
of significant polymorphism in the non-classical MHC class I allele described here strongly 299 
suggests that this complex is not involved in antigen presentation, and is thus more likely to interact 300 
with NK receptors, as has been observed for a number of non-classical class I gene products in 301 
human and other species. Cattle have recently been shown to have a family of genes with homology 302 
to the human KIRs (McQueen and Parham, 2002; Storset et al., 2003), and several other putative 303 
NK receptors have been identified (Storset et al., 2004), but thus far interactions between these 304 
putative NK receptors and MHC class I molecules have not been demonstrated.  305 
Thus while it is possible to speculate that the lack of interaction of E5 with N*50001 constitutes a 306 
viral mechanism for evading NK recognition, this remains to be confirmed. Nevertheless, down-307 
regulation of classical MHC class I and lack of down-regulation of non-classical MHC class I by E5 308 
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strongly suggest that the viral protein is instrumental for the establishment of viral infection by 309 
allowing the infected cell to escape both the adaptive and innate immune response of the host.  310 
 311 
 312 
Materials and Methods 313 
Plasmids. N*01301 cDNA, encoding heavy chain (HC) N*01301 (formerly HD6), was cloned both 314 
in pcDNA3 (Ellis et al., 1999) and pcDNA6-V5-His (Invitrogen, Paisley, UK). Full-length clones 315 
of N*50001 cDNA (AY 188807), encoding N*50001, were generated by PCR from cattle PBMC 316 
cDNA. This class I gene is very prone to alternative spicing, and the most common splice variant 317 
was used in this study. Multiple clones were sequenced and a clone containing the consensus 318 
sequence was introduced into pcDNA6-V5-His (Figure 1). 319 
pz4E5 and pc4E5 are plasmids carrying the ORF of BPV-4 E5 under the transcriptional control of 320 
the murine MLV LTR or the IE promoter of HCMV respectively. These plasmids have been 321 
described before (Ashrafi et al., 2002; Pennie et al., 1993). 322 
Cells. P815 cells are a mouse mastocytoma cell line (ATCC). They are grown in suspension in 323 
RPMI 1640 supplemented with 10% FCS. Stable transfectants expressing N*01301 were produced 324 
by transfection of pcDNA6-V5-His N*01301, and maintained under blasticidin selection. These 325 
cells are designed P815-N*01301. Stable P815 transfectants expressing N*50001 were generated as 326 
described before (Ellis et al., 1999), and positive cells were identified using blasticidin selection, 327 
screening by western blotting with an anti-V5 monoclonal antibody (mAb) (Invitrogen), and flow 328 
cytometry. These cells are designated P815-N*50001. Both P815-N*01301 and P815-N*50001 329 
were transfected with either pz4E5 or pc4E5, or the corresponding empty vectors, with an Amaxa 330 
nucleofector (Amaxa GmbH) using the kits and following the instructions supplied by the 331 
manufacturers. Cells were selected by G418 resistance and stable transfectants were isolated.  332 
Quantitative RT-PCR (Q-RT-PCR) 333 
 14
RNA was extracted from P815 cells using RNeasy mini Kit (Qiagen, UK) and residual DNA was 334 
inactivated using DNase I treatment (Invitrogen). Q-RT-PCR for BPV-4 E5 and mouse β-actin 335 
mRNA was carried out using the Taqman EZ  RT-PCR Kit (Applied Biosystems, Foster City, CA). 336 
Each reaction was performed in triplicate using 100ng of RNA. Oligonucleotide primers, designed 337 
using Primer Express (v 1.7, Perkin Elmer, Oak Brook, IL), were as follows:  338 
BPV4 E5 F5'-TGTCTTTGTGGCTTATCTATGTTTTGT-3';  339 
BPV-4 E5 R5'-CCGAGTAATAGTAGAAATTAACAGAAGGTACAC-3'; and FAM/ TAMRA probe 5'-340 
CTTTTCTGGTGTGCTTTTAATTTTCTTGCACTGTTA-3'.   341 
β-actin F5'-GCTCTGGCTCCTAGCACCAT-3';  342 
β-actin R5'-GCCACCGATCCACACAGAGT-3' and FAM/ TAMRA probe 343 
5'-AAGATCATTGCTCCTCCTGAGCGAAAG-3'.  344 
PCR reactions were performed using an ABI prism 7700 sequencer. Standard curves were 345 
generated using 10-fold serial dilutions of each template DNA, which were used for quantifying the 346 
relative levels of E5 and β-actin RNA.  347 
Flow cytometric analysis of MHC class I expression  348 
P815-N*01301 and P815-N*50001 cells either expressing BPV-4 E5 or carrying empty vector were 349 
grown in suspension in T175 cm2 flasks until subconfluent. Following centrifugation, the cell pellet 350 
was washed with PBS and resuspended in PBS/1% bovine serum albumin (PBS-B) at a 351 
concentration of 106 cells/ml. For the detection of surface MHC class I molecules, aliquot of 106 352 
cells were incubated for 1h at 4ºC with monoclonal antibody (mAb) IL-A88, specific for bovine 353 
MHC class I (Toye et al., 1990) in PBS-B. After washing twice with PBS, cells were incubated with 354 
1:100 dilution of anti-mouse IgG-FITC (Sigma, UK) for 30 min at 4ºC in the dark. The cells were 355 
washed as above, resuspended in 500 µl PBS and analysed by flow cytometry. If the flow 356 
cytometry analysis was not carried out immediately, the cells were resuspended in 500 µl of 3% 357 
paraformaldehyde in PBS and kept at 4ºC. P815 cells not expressing bovine MHC class I were used 358 
as control, as well as cells incubated without primary antibody.  For the detection of intracellular 359 
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MHC class I, the cells were permeabilised with 0.1% saponin in PBS-B for 30 min at RT and then 360 
incubated with primary antibody as described above. All samples were examined in a Beckman 361 
coulter EPICS Elite analyzer equipped with an ion argon laser with 15mV of excitation at 488 nm. 362 
Data were analyzed using Expo 2 software. 363 
Localisation of MHC class I in P815 cells by immunofluorescence 364 
An eight-well slide (Chamber Slides Lab-tek, VWR International) was washed with alcohol, air-365 
dried and treated with 40µl/well poly-L lysine hydrobromide (Sigma) for 10 minutes to allow 366 
adhesion of the cells. After removal of poly-L lysine, the slide was washed with distilled water and 367 
air-dried. P815 cells were pelleted, washed twice in PBS and resuspended in fixing solution (5% 368 
formaldehyde in PBS containing 2% sucrose) for 10 minutes. After two washes, the cells were 369 
plated in PBS containing 1% FCS, at 1x102 cells/well, and left for 15 minutes to settle down. After 370 
removal of PBS, the cells were treated with permeabilising solution (0.01% Tween-20 in PBS) for 371 
10 minutes. The Golgi apparatus was visualised with 1:1000 dilution of BODIPY Ceramide Texas 372 
Red (TR) (in 2.5% Hepes in serum-free 1640 RPM medium) for 30 min at 4ºC. BODIPY Ceramide 373 
specifically locates to the Golgi apparatus. After removal of BODIPY Ceramide, cells were 374 
incubated in 2.5% Hepes in serum-free 1640 RPM medium for 30 min at 37ºC. For detection of 375 
MHC class I, cells were first incubated with IL-A88 antibody for 1h at RT followed by incubation 376 
with 1:1000 dilution of anti-mouse IgG-FITC for 1h in dark with two washes in between. The cells 377 
were washed three times and the slide was mounted with a 60mm coverslip using citifluor. 378 
Imaging 379 
Images were captured using a Leica TCS SP2 true confocal scanner microscope (Leica 380 
Microsystems, Heidelberg, Germany) at a wavelength of 488 nm (MHC class I: FITC) or 543 nm 381 
(Golgi apparatus: Texas Red). The merge between the fluorescent signals was achieved using the 382 
accompanying software. 383 
Immunoblotting  384 
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P815 cells were lysed in 300µl of lysis buffer (0.5% NP40, 50mM Tris PH 7.8, 150mM NaCl) 385 
containing a protease inhibitor cocktail (Roche, Lewes, UK). Following incubation on ice for 30 386 
min, the cell debris was eliminated by centrifugation and the protein concentration was measured 387 
using the BCA/CuSO4 assay. To determine the stability of classical and non-classical bovine MHC 388 
class I heavy chain in P815 cells, aliquots of 2x 106 cells were treated with 100µg/ml 389 
cyclohexamide (Sigma) or the solvent DMSO (Sigma) for different periods of time at 37ºC. The 390 
cells were washed with ice cold PBS, pelleted and resuspended in 100µl of lysis buffer as described 391 
above. 392 
The protein samples were mixed with 4x NuPAGE® SDS sample buffer (40% Glycerol, 500mM 393 
Tris-HCl (pH 6.8), 8% SDS, 0.075% Serva blue G250, 0.025% phenol red), and 10x NuPAGE® 394 
Reducing Agent (0.5M DTT). The samples were heated at 70ºC for 10 minutes before loading in 395 
NuPAGE® 4-12% Bis-Tris-HCl (pH 6.4) poly-acrylamide gels (Invitrogen Ltd). Electrophoresis 396 
was performed in MES SDS Running buffer (Invitrogen Ltd) at a constant voltage 200V for 60 397 
minutes. 398 
Separated protein samples were transferred to nitrocellulose membranes by wet electrophoretic 399 
transfer using a Xcell IITM blotting apparatus (Invitrogen Ltd) as per manufacturer’s instructions. 400 
The blotting was performed at a constant voltage of 30V for 80 minutes in 1x NuPAGE® transfer 401 
buffer containing 10% methanol. Transfer was checked by staining the nitrocellulose membrane 402 
with Ponceau S solution (Sigma).  403 
Membranes were blocked in 5% milk in Tris buffered saline (TBS) containing 0.05% Tween 20 (T-404 
TBS) for 1h at RT or overnight at 4ºC. For detection of MHC class I, the membranes were 405 
incubated with mAb IL-A88 in 5% milk in T-TBS for 2 hours at RT. After two washes in T-TBS, 406 
the membranes were incubated with 1:5000 dilution of horseradish peroxidase-linked sheep anti-407 
mouse IgG whole antibody (Amersham Biosciences) in 5% milk in T-TBS for 1 hour at RT. Bound 408 
antibody was detected by incubating the membrane for 5 minutes at RT with ECL plus western 409 
blotting detection system (Amersham Biosciences) according to the manufacturer’s instructions. 410 
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After exposure, bound antibody was removed from the membranes with stripping buffer (100mM 2-411 
Mercaptoethanol, 2% SDS, 62.5mM Tris-HCl pH6.7) at 50ºC for 30 minutes. After washing in T-412 
TBS, the membranes were blocked in 5% milk in T-TBS for 1 hour at RT prior to re-probing with 413 
1:20,000 dilution of anti-actin antibody (mAb Ab-1; CALBIOCHEM). After incubation with mAb 414 
Ab-1, the membranes were washed two times in T-TBS and incubated with anti-mouse IgG linked 415 
to horseradish peroxidase as described above. 416 
Co-immunoprecipitation.  417 
a. In vitro transcription/translation and co-immunoprecipitation. 418 
In vitro transcription/translation reactions were performed using the TNT® T7 Quick Coupled 419 
Transcription/Translation System (Promega, UK) in presence of Redivue L-[35S] Methionine 420 
(Amersham Pharmacia Biotech, UK) following the manufacturer instructions. Briefly, 1 μg of 421 
pc4E5, pcDNA3-N*01301 or pcDNA6-V5-His-N*01301, or pcDNA6-V5-His-N*50001 was mixed 422 
in a 50μl reaction containing TNT® mix (TNT® lysate with energy generating system, T7 RNA 423 
polymerase, nucleotides, salts, recombinant RNasin® ribonuclease inhibitors) in presence of canine 424 
microsomal membranes (CMM) (Promega, UK) at 30oC for 1.5 h. Half of each 425 
transcription/translation reaction product was immunoprecipitated with either 10 μl rabbit antiserum 426 
Ab 274, raised against the C-terminus of the BPV-4 E5 protein (Anderson et al., 1997; Pennie et al., 427 
1993) or with 3 μl mAb IL-A88. The other half of each reaction was left without antibody as a 428 
negative control. For co-immunoprecipitation experiments, the individual transcription/translation 429 
products were mixed in equivalent amounts and immunoprecipitated with double the amount of 430 
either antibody. For competition experiments, no [35S] Methionine was added to the reaction 431 
containing pcDNA3-N*50001 and the unlabelled N*50001 was added to labelled E5 for an hour 432 
before the addition of labelled N*01301 as above. After incubation overnight at 4oC, protein G-433 
sepharose bead suspension (Sigma) was added for 1 h at 4oC. Following two washes in a high salt 434 
buffer (50mM Tris HCl pH 7.5, 500mM NaCl, 1% NonidetP-40, 0.05% NaDoc) and one wash in a 435 
low salt buffer (50mM Tris HCl pH 7.5, 1% NonidetP-400, 0.05% NaDoc) the sepharose beads 436 
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were resuspended in 20 μl of SDS loading buffer, heated at 75oC for 10 min, and then were 437 
electrophoresed in 4-12% NuPAGE gels (Invitrogen). Gels were fixed with glacial acetic acid and 438 
methanol, incubated for 15 min in AmplifyTM Fluorographic reagent (Amersham, UK), dried and 439 
exposed for autoradiography at –70oC overnight or exposed on a screen for quantification on a 440 
Storm 840 apparatus using a ImageQuant v5.2 software. 441 
b. “Pull-down co-immunoprecipitation”.  442 
Protein lysates were obtained from P815, P815-N*01301 and P815-N*50001 cells. Cells were lysed 443 
in RIPA buffer containing a cocktail of protease inhibitors (Roche, Lewes, UK). Protein lysates 444 
(100 μg) were incubated with in vitro 35S-labelled E5 overnight at 4oC and immunoprecipitated 445 
with mAb IL-A88 as described above. Immunopreciptates were electrophoresed in 4–12% 446 
NuPAGE gels (Invitrogen). Gels were fixed with glacial acetic acid and methanol, incubated for 15 447 
min in Amplify Fluorographic reagent (Amersham, UK), dried and exposed for autoradiography at  448 
-70oC overnight.  449 
 450 
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Figure Legends 549 
Figure 1. Alignment of the predicted amino acid sequences of N*01301 and N*50001 (splice 550 
variant). Dots indicate identity, * indicates stop codon. Divergent amino acids (bold) are seen only 551 
in N*50001 (or other cattle non-classical class I alleles) and are not seen in cattle classical class I 552 
alleles (www.ebi.ac.uk/ipd/mhc/bola/). Four additional amino acids at the end of the alpha 3 domain 553 
of N*50001 are the result of incorrect splicing of intron 4. 554 
Figure 2. BPV-4 E5 ORF is transcribed at comparable levels in all P815 cells. E5 and β-actin RNA 555 
was measured by Q-RT-PCR. The histograms represent the average with standard deviation of six 556 
independent measurements. Note that the levels of E5 RNA are three orders of magnitude lower 557 
than those of β-actin RNA.  558 
Figure 3. BPV-4 E5 down-regulates surface and total classical N*01301 MHC class I but not non-559 
classical N*50001 MHC class I. A, example of flow cytometry profiles of surface and total classical 560 
N*01301 and non-classical N*50001 MHC class I in P815 control cells or cells expressing E5. B, 561 
mean forward fluorescence with standard deviation calculated from the flow cytometry profiles of 562 
at least three independent experiments in duplicate.  563 
Figure 4. BPV-4 E5 induces degradation of classical N*01301 MHC class I heavy chain but not 564 
non-classical N*50001 heavy chain. A, steady state levels of classical N*01301 and non-classical 565 
N*50001 heavy chain in P815 control cells or cells expressing E5. B, half-life measurement of 566 
classical N*01301 and non-classical N*50001 heavy chain in cycloexamide-treated P815 control 567 
cells and cells expressing E5. HC, heavy chain. 568 
Figure 5. BPV-4 E5 induces retention of classical, but not non-classical, MHC class I in the Golgi 569 
apparatus. A, immunofluorescent detection of classical and non-classical MHC class I in P815 570 
control cells or cells expressing E5.  571 
Figure 6. BPV-4 E5 interacts with classical N*01301 heavy chain but fails to interact with non-572 
classical N*50001 heavy chain. A, 35S-labelled in vitro transcribed/translated E5 and N*01301 HC 573 
or N*50001 HC were immunoprecipitated with mAb IL-A88, against MHC class I heavy chain; the 574 
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precipitate was run in a NuPAGE gel and the dried gel exposed on a screen on a Storm 840 575 
apparatus. Classical N*01301 HC interacts with E5 (lane 3), while non-classical N*50001 HC fails 576 
to interact with E5 (lane 5) and to compete with classical N*01301 HC for binding to E5 (lane 9). 577 
Several additional bands are visible which derive from the translation of the proteins (see input 578 
lanes) which may be due to dimers or multimers of E5 or to degradation products of HC. B, “Pull-579 
down co-immunoprecipitation” between E5 and N*01301 HC. Protein extracts from P815, P815-580 
N*01301 and P815- N*50001 cells were incubated with 35S-labelled in vitro transcribed/translated 581 
E5 and precipitated with mAb IL-A88. E5 is precipitated from P815-N*01301 cells (lane 2) but not 582 
from P815 parental or P815-N*50001 cells (lanes 3 and 4). 583 
 584 
 585 
          
                          Alpha 1                                               
                   *         20         *        40         *              
N*01301 : LFMLLLGALVLIETRA│GSHSLRYFHTAVSRPGLREPLFITVGYVDDTQFVRFDSDAR    
N*50001 : .LL....V..PRD...│.P..M...L........G..R..................RP    
                            
                                               
                                                           Alpha 2              
           60         *        80         *       100          *           
N*01301 : DPRTEPRQPWMEKEGPEYWDRETQISKENALWYREALNNLRGYYNQSEA│GSHTLQEM   
N*50001 : ...M...AR.V.D.......Q..R.Q...TQTF.AN..T.L........│...I..W.   
                                                                          
 
                                                                          
             120         *       140         *       160         *        
N*01301 : YGCDVGSDGRLRRGYEQYGYDGRDYLALNEDLRSWTAADTAAQISKRKMEAAGAAER   
N*50001 : H..G.......L...N.HA...K.....................T...W..T.....   
 
                                                                          
                                     Alpha 3                                    
                180         *        200         *       220               
N*01301 : FRNYLEGTCVEWLRRYLENGKDTLLRA│DPPKAHVTRHPSSEHEVTLRCWALGFYPEE   
N*50001 : .......K..KL...H...........│...M....H..I..R...............   
 
                                                                          
                                                                          
           *       240         *       260         *       280            
N*01301 : ISLTWQRNGEDQTQDMELVETRPSGDGNFQKWAALVVPSGEEQRYTCRVQHEGLQEP   
N*50001 : ...........................T.......A.....................   
 
                                                                          
               Transmembrane domain                Cytoplasmic domain                     
              *        300         *       320          *       340         
N*01301 : LTLRW----│EPPQTSFLTMGIIVGLVLLVVAVVAGAVIWMKKHS│GEKRRTYTQAASNDSAQ   
N*50001 : .....DKGG│....P.VPI....LV...............S..R.│...G.I..*   
 
                                                                          
                           
                 *         
N*01301 : GSDVSLTVPK*   
N*50001 :      
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